Spondyloarthritis & psoriatic arthritis
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
Authors' conclusion
The PsAID-12 demonstrated robust psychometric properties in a large sample of patients with active PsA, supporting its use as a fit-for-purpose patient-reported outcome in this population.
Study context
- Population
- Patients with active PsA enrolled in two RCTs of bimekizumab (BE OPTIMAL and BE COMPLETE), data up to week 16
- Participants
- 1,252 patients2 RCTs
- Outcome
- Psychometric performance of PsAID-12
Methodological detailspooled analysis of two phase 3 RCTs, pooled data, anchor-based and distribution-based analyses, ROC curve analyses
- Pooled analysis of two phase 3 RCTs
- Pooled data
- Anchor-based and distribution-based analyses
- ROC curve analyses
Performance
As reported in the abstract
- Baseline Psoriatic Arthritis Impact of Disease (PsAID-12) total score, mean (SD)
- 4.19 (1.94)
- Internal consistency reliability, Cronbach's alpha
- 0.95
- Test-retest reliability, ICC
- ≥ 0.70
- Responsiveness acceptable (correlations for most scores)
- ≥0.30
- Improvement threshold, PsAID-12 total score (points)
- 1.5-2
- Improvement threshold, item scores (points)
- 2 or 3
Original publication
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis. RMD Open. Published 31 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →